Literature DB >> 19387826

Effects of short-term nocturnal cortisol replacement on cognitive function and quality of life in patients with primary or secondary adrenal insufficiency: a pilot study.

Birgit Harbeck1, Peter Kropp, Heiner Mönig.   

Abstract

Cortisol replacement in patients with adrenal insufficiency usually consists of hydrocortisone (HC) given orally during day time. Due to the short half-life of hydrocortisone, cortisol levels between midnight and early morning are very low in contrast to the physiological rise of cortisol serum levels during this time. We investigated whether short-term cortisol replacement during the night improves cognitive function and well-being in these patients. Fourteen patients with adrenal insufficiency were put on HC infusion between midnight and 8 a.m. They subsequently underwent neurocognitive testing to measure intellectual functioning, concentration, memory and fine motor skills. Quality of life and mood were also evaluated. All tests were repeated after 2-4 weeks during usual oral glucocorticoid replacement therapy. Blood samples were taken for cortisol, epinephrine and norepinephrine measurement. With the exception of the digit symbol test with better scoring in the oral group (p = 0.005) there were no significant differences in neurocognitive testing, vegetative functions and quality of life on the two occasions. However, a higher cortisol level was associated with a worse performance in short-term memory. Plasma epinephrine concentration was subnormal in both groups, but increased only after intravenous hydrocortisone replacement. Mimicking the physiological rise in cortisol secretion during the night in this pilot study did neither significantly affect quality of life nor cognitive performance and vegetative functions. There was no improvement in general well being. Hydrocortisone infusion during night time might improve adrenomedullary reserve in patients with adrenal insufficiency.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19387826     DOI: 10.1007/s10484-009-9082-5

Source DB:  PubMed          Journal:  Appl Psychophysiol Biofeedback        ISSN: 1090-0586


  8 in total

Review 1.  Adrenal insufficiency: etiology, diagnosis and treatment.

Authors:  Nicola Neary; Lynnette Nieman
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2010-06       Impact factor: 3.243

2.  Effect of hydrocortisone replacement therapy on body mass index after pituitary surgery.

Authors:  B Harbeck; C S Haas; H Mönig
Journal:  J Endocrinol Invest       Date:  2014-11-29       Impact factor: 4.256

3.  Adrenal insufficiency treated with conventional hydrocortisone leads to elevated levels of Interleukin-6: a pilot study.

Authors:  Amir-Hossein Rahvar; Martin Riesel; Tobias Graf; Birgit Harbeck
Journal:  Endocrine       Date:  2019-05-17       Impact factor: 3.633

4.  Dual-release hydrocortisone and its benefits on cognitive function and quality of sleep.

Authors:  Clarissa Krekeler; Peter Kropp; Antje Katrin Blacha; Amir-Hossein Rahvar; Birgit Harbeck
Journal:  Endocrine       Date:  2021-02-24       Impact factor: 3.633

5.  Episodic memory impairment in Addison's disease: results from a telephonic cognitive assessment.

Authors:  Michelle Henry; Kevin G F Thomas; Ian L Ross
Journal:  Metab Brain Dis       Date:  2014-02-27       Impact factor: 3.584

6.  Poor quality of life, depressed mood, and memory impairment may be mediated by sleep disruption in patients with Addison's disease.

Authors:  Michelle Henry; Pedro S A Wolf; Ian L Ross; Kevin G F Thomas
Journal:  Physiol Behav       Date:  2015-08-07

Review 7.  Sleep, Cognition and Cortisol in Addison's Disease: A Mechanistic Relationship.

Authors:  Michelle Henry; Kevin Garth Flusk Thomas; Ian Louis Ross
Journal:  Front Endocrinol (Lausanne)       Date:  2021-08-27       Impact factor: 5.555

8.  Poor quality of life and sleep in patients with adrenal insufficiency-another cause of increased mortality?

Authors:  Antje K Blacha; Peter Kropp; Amir H Rahvar; Jörg Flitsch; Iris van de Loo; Birgit Harbeck
Journal:  Ir J Med Sci       Date:  2021-08-13       Impact factor: 2.089

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.